Rare Epilepsies and Advances in Diagnoses (READ)
Saturday, December 4, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
READ is a 90-minute, Takeda-sponsored roundtable discussion covering the nosology of Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS), and their diagnoses and future diagnostic innovations.
1. What is the need? Nosology of DEEs
a. While DS diagnosis is well-established, further classification of diagnostic criteria for LGS is needed because it has multiple etiologies; this presents a challenge in defining LGS
b. Paving a road for accurate diagnosis of LGS can assist with earlier disease detection
2. What is available? Summarize existing registries and databases
a. Discuss updates to EpiCARE ERN (along with other available registries) and natural history studies for LGS and DS
b. Discuss the implications of the new ICD-10 code for DS in the US
3. What is the future? Innovations in LGS and DS diagnosis
a. The potential use of AI and machine learning to empower the ability to identify symptoms early
b. Their potential application in wearable devices to detect seizures
Sponsor: Takeda Pharmaceutical Company Limited
Learning Objectives:
Following participation in this activity, learners will be able to:
- Discuss nosology of DS and LGS, the challenges in diagnosing DEEs (including DS and LGS), and the future pathway for diagnosis
- Identify existing registries and the heterogeneity of LGS data in these registries
- Explore of AI and machine learning to identify DS and LGS patients, along with their application in audio and visual methods for identifying seizures